Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease
BOSTON, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for A197...